• Tubulis

  Participated · Series B · Mar 2024

  Tubulis is a Munich-based biotechnology company engineering uniquely matched antibody-drug conjugates with enhanced biophysical properties for improved on-tumor delivery and wider therapeutic windows. Its proprietary Tubutecan and other ADC platform technologies underpin a growing pipeline designed for high-need solid tumor indications. The lead program, TUB-040 targeting NaPi2b, has shown early clinical proof-of-concept in platinum-resistant high-grade serous ovarian cancer, demonstrating anti-tumor activity at low doses with favorable safety. A second clinical-stage candidate, TUB-030, targets 5T4, and several additional ADCs remain in preclinical development. Proceeds from the company’s latest financing will fund pivotal trials of TUB-040, evaluations in earlier-line ovarian cancer, combination regimens and broader solid tumor exploration. The capital will also advance TUB-030 and preclinical assets while driving further innovation of Tubulis’ ADC technologies for internal programs and partnerships. To date, the firm has secured €344 million (US $401 million) in Series C funding from a global syndicate of life-science investors.

• Quantum Systems

  Participated · Series B · Oct 2023

  Quantum Systems develops an interoperable family of unmanned platforms across air, land, and sea domains unified by its MOSAIC UXS tactical software command ecosystem. The company operates as a deep-tech defense prime and has deepened strategic industrial collaboration with Airbus Defence and Space. It reports having achieved double-digit profitability alongside triple-digit revenue growth and has expanded its global corporate production footprint across Germany, Ukraine, the United States, Australia, Romania, the United Kingdom, and the Baltics. Led by co-CEOs Florian Seibel and Sven Kruck, the company is investing in scaling physical manufacturing and software R&D. The Series D financing will support expansion of manufacturing capacity, bolster supply chain resilience, and accelerate its software roadmap.

• Tidely

  Participated · Equity · Mar 2023

  Tidely offers an AI-based digital platform for small and medium-sized enterprises that provides liquidity planning, cash flow analysis, cost management, and real-time liquidity insights. The product uses artificial intelligence to reduce errors in liquidity planning and generates forecasts based on past developments. Users can run scenario-based sensitivity analyses to quantify the effects of planned investments and other measures on future liquidity. The company says the platform aims to make modern, comprehensive, and user-friendly liquidity management accessible to more SME customers. Tidely plans to use the new funding to further develop the product, expand marketing and sales channels, and strengthen its team. As of the article the company serves around 500 SMEs, has about 20 employees, and was founded in 2018 by Niclas Storz and Dr. Joerg Haller in Munich, Germany.

• Nylas

  Participated · Series B · Aug 2018

  Nylas is a communications API platform that enables developers to integrate email, calendaring, scheduling and other productivity tools into applications with a few lines of code. Its product set includes email integrations for major providers (including IMAP), scheduling and calendaring APIs, a neural API for sentiment analysis and workflow automation, and security integrations to streamline OAuth reviews. The company processes roughly 1.2 billion API requests per day, moving about 20 terabytes of data daily, and reports 80,000 developers using its platform. Revenue growth has tripled in the past 12 months, though the company is not disclosing a valuation for this round. Nylas plans to use the new funding to expand the types of APIs it offers, with a particular focus on AI and automation to drive more workflow efficiency. The platform targets businesses seeking to reduce the time and complexity of building integrations between siloed productivity tools and their own applications. Nylas offers a universal communications API platform that lets developers connect applications to every email, calendar, and contacts provider and process unstructured communications data in days. The company says its solution saves customers an average of 16 months and $2M in up-front development costs and provides SOC 2 certified, GDPR compliant, Privacy Shield certified, and HIPAA- and FINRA-ready integrations. Over 40,000 developers use Nylas to process more than 1.2 billion API requests and sync 15TB of data daily, and the company serves over 450 customers including Comcast, Hyundai, Realtor.com, Dialpad, Freshworks, Pipedrive, Qualia, and Clio. Nylas recently acquired June.ai and is integrating its AI-powered productivity tools to expand the platform into intelligent workflow automation. The company plans to use new funding to scale sales and marketing and accelerate product innovation. Nylas also plans to double its workforce over the next 12 months and is hiring across San Francisco, New York City, and Denver while building a dedicated engineering team in Toronto. Nylas offers an API that lets developers connect to email, calendar and contact information from services like Gmail, Microsoft Exchange and IMAP providers. The company builds adapters for native protocols and backend providers (Google, GoDaddy, Yahoo) to simplify access to mailbox data. Its product is used to pull data for use cases such as CRM integration and multi-person meeting coordination. Nylas has been around for five years and operates with offices in New York and San Francisco. The company currently has 35 employees, counts 200 customers and serves thousands of developers. With new funding, Nylas plans to double headcount by the end of the year and expand engineering, sales and marketing efforts to reach more corporate customers. Nylas provides APIs for email, calendars, and contacts that enable bi-directional email sync and send features in SaaS products. Its platform integrates with all email service providers and targets marketing, sales and recruiting professionals. The company has synced more than 100 terabytes of data from more than 15 billion emails. Nylas' APIs power features across CRM, marketing automation, recruiting, scheduling, legal and real estate platforms. Founded in 2013 by Gleb Polyakov (CEO) and Christine Spang (CTO), the company is based in San Francisco, CA. Nylas plans to use the funds to grow its team, expand its reach, and further invest in the Nylas API products.

• Lophius Biosciences

  Participated · Equity · Jul 2011

  Lophius Biosciences develops and markets T cell-based diagnostic systems to improve therapy control and personalize treatment for transplantation, infectious and autoimmune diseases. Its product portfolio includes the CE-marked in vitro diagnostic solution T-Track® CMV to personalize antiviral CMV therapy in transplant patients and diagnostic efforts based on its Reverse T Cell Technology (RTT) platform. The RTT platform enables differentiation of active T cells versus T memory cells; Lophius recently completed a proof of concept study for differential diagnosis of tuberculosis that distinguishes active contagious disease from latent infection. The company will use the extended funding to accelerate diagnostic developments in the tuberculosis area, further leverage its T cell and immunodiagnostic technology platforms, and strengthen commercialization activities for T-Track® CMV. Lophius completed an additional financing that brought its latest round to €7.4m after a further €2.2m injection. The company is led by CEO Bernd Merkl and is based in Regensburg, Germany. Lophius Biosciences develops and markets T cell–based research tools, contract research solutions and diagnostics for functional assessment of pathogen- and disease-reactive T cells. Its product portfolio includes the T Cell Tool, contract research services and a diagnostic development program based on its proprietary Reverse T Cell Technology. The Reverse T Cell Technology enables differentiation of in‑vivo activated T cells versus T memory cells and, in tuberculosis, allows identification of patients with contagious active disease versus latent infection. Lophius completed a €4.25M financing round led by VRD GmbH with participation from the Bavarian Growth Fund (Wachstumsfonds Bayern) of Bayern Kapital, Wolf Biotech GmbH and WIC GmbH. The company will use the proceeds to expand its in‑vitro diagnostic programs to tuberculosis and to further strengthen market penetration activities for its T Cell Tool and contract research portfolio. Lophius is led by co‑CEOs and Managing Directors Bernd Merkl and Robert Phelps and is based in Regensburg, Germany. Lophius Biosciences, based in Regensburg, Germany, develops and markets innovative T cell-based diagnostic systems. Its flagship product is T-Track® CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in CMV seropositive transplant patients undergoing immunosuppressive therapy. The company also has pipeline products T-Track® TB (Tuberculosis) and T-Track® MS (Multiple Sclerosis). Lophius raised €2M in financing to further advance the clinical studies of T-Track® CMV and to enable further development of its pipeline products. Leadership changes accompanied the financing, with Dr. Robert Phelps named CEO and Prof. Dr. Ralf Wagner appointed Chairman of the Board to help create the commercial organization. Lophius Biosciences is a Regensburg, Germany-based developer and marketer of novel T-cell-based diagnostic test systems led by CEO Dr. Michael Lutz. The company focuses on diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases. It is bringing its T-Track© CMV/EBV tests to market for use in transplantation. Lophius plans further development of a diagnostic test for the differential diagnosis of tuberculosis. The company is also developing a novel, blood-based multiple sclerosis test. Financially, Lophius closed a €1.4m financing round subscribed by existing investors S-Refit, High‑Tech Gründerfonds and Bayernkapital. Lophius Biosciences develops and markets T-cell-based diagnostic test systems for diagnosis and potential therapy guidance in transplantation, infectious and autoimmune diseases. The company is a spin-off of the Universitätsklinik Regensburg and is based in Regensburg, Germany. It uses proprietary technology platforms to generate diagnostic tests and plans to commercialize existing products while developing new assays. To support these activities, Lophius closed a €1.6m second financing round. The funds are intended to boost development with a strong focus on commercialization of existing diagnostic products and the generation of new tests. In conjunction with the financing the company appointed Dr. Michael Lutz as CEO, with PD Dr. Deml and Marc Akteries remaining in leading roles.

No current team members are available.